Skip to content

Trial Objectives


Pulmonary arterial hypertension, or PAH, is a serious condition where blood pressure in the lungs is unusually high, forcing the heart to work harder. The current best way to diagnose PAH is an invasive procedure called a right heart catheterization, which is not typically approved just for early diagnosis. The delay in diagnosis leads to worse health outcomes, so researchers are investigating a new way to potentially detect PAH earlier using a retinal scan to measure blood pressure in the eyes.

Volunteers in this study will receive retinal scans to look at the blood vessels in their eye and will receive blood testing. These tests will be repeated over two clinic visits to help track changes in the blood vessels, which will help researchers determine if this data can predict if PAH will develop or worsen over time.

Who Can Participate


Adults with a diagnosis of pulmonary arterial hypertension or who are at risk of developing PAH due to having systemic sclerosis, scleroderma, a relative with PAH or a genetic risk factor.  

Age: 18+ Gender: Any

Estimated Time Commitment


Two study visits over 6 months if you have PAH, or 12 months if you are at risk of PAH

Payment & Reimbursement


Payment: Provided

Travel Reimbursement: Not Available

Trial Contact


For more information, contact:


Jennifer Underwood
303.398.1518

Request More Information

Trial Location


National Jewish Health main campus, University of Colorado Anschutz campus

Trial Sponsors


American Heart Association (AHA)

Principal Investigators

Tim Lahm

Tim Lahm, MD, ATSF

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required